Price Premium May Pose Hurdles for Arena, Eisai’s Belviq Similar to Vivus’ Qsymia

Compiled by Andrew Berens, MD, Senior Healthcare Analyst, Bloomberg Industries and Elizabeth Krutoholow

Arena and Eisai’s decision to price obesity drug Belviq at a premium to competitor Vivus may create a hurdle for the companies without broad coverage from insurers.

Eisai disclosed that the wholesale acquisition cost of Belviq has been set at $199.50 for a bottle of 60 10mg tablets, or a one-month supply. This compares to Vivus’s Qsymia, which retails for $160 for a month of medium-dose therapy and $220 a month for high-dose therapy.



Bloomberg BRIEF Newsletters